Polymorphisms of tumour necrosis factor superfamily member 11 (TNFSF11) gene, that codes for RANKL, were found in our previous research (Mencej S et. al. 1006). In this study we demonstrated , that variations in the TNFSF11 gene promoter could alter its expression and play a functional role in the genetic regulation of BMD.
COBISS.SI-ID: 2383985
To get insight into gene expression of cathepsin K, MMP-9, TRAP, RANKL, OPG, and osteocalcin we extracted mRNA from the bone samples (proximal femur obtained at surgery) in patients with osteoarthritis and osteoporosis. Gene expression of proteins studied and the association between their mRNA levels pointed to higher bone resorption and bone formation in osteoarthritis, differences in balance between them, and differences in regulation of bone resorption in osteoarthritic and osteoporotic bone.
COBISS.SI-ID: 2152305
OPG plays a crucial role in the control of bone resorption and its gene could therefore be a good candidate gene for osteoporosis. In a ppulation of postmenopausal women we detected eight polymorphisms in the OPG gene, two of them were described for the first time. According to our analysis polymorphism 1181G)C is associated with limbar spine BMD and could therefore be considered as an element of genetic susceptibility to osteoporosis
COBISS.SI-ID: 3106330
We were the first to demonstrate that therapy with insulin sensitizers with well-known clinical, hormonal and metabolic efficacy resulted in marked improvement in adipose tissue GLUT4 mRNA expression in PCOS patients.
COBISS.SI-ID: 2254961
We were the first to demonstrate that therapy with insulin sensitizers resulted in marked improvement of endothelial function in young PCOS patients as assesed by endothelium-dependent flow-mediated dilatation (FMD) and glyceryl trinitrate-induced endothelium-independent dilatation. This might imply that therapeutic intervention with insulin sensitizer may reverse the atherosclerotic process in PCOS patients at its early stage.
COBISS.SI-ID: 24580313